

North Yorkshire & York Area Prescribing Committee

Wednesday 6th September 2023
2pm – 4.30pm, virtual meeting via Microsoft Teams

Present

Name	Job Title	Organisation	Voting Member	May 2023	Jun 2023	Jul 2023	Aug 23	Sep 2023	
Ken Latta	Head of Medicines Optimisation	North Yorkshire Place	Y	Y	Y	Y	Apols	Y	
Dr Tim Rider	GP Prescribing Lead	North Yorkshire Place	Y	Y	Apols	Y	Y	Y	
Laura Angus	Head of Medicines Optimisation and Interim Chief Pharmacist at Humber, & North Yorkshire ICS	City of York Place	Y	Y	Y	Y (note Chris Ranson held voting rights)	Y (note Chris Ranson held voting rights)	Y (note Chris Ranson held voting rights)	
Dr Shaun O'Connell	GP Lead for Acute Service Transformation	City of York Place	Y	Apols	Apols	Apols	Apols	Apols	
Dr William Ovenden	GP	City of York Place	Y	Apols	Y	Y	Y	Apols	
Kate Woodrow	Chief Pharmacist	Harrogate and District NHS Foundation Trust	Y	Y	Sara Moore	Y	Apols	Y	
Dr Ben Walker (till Feb 2023)	Consultant and D&T Chair	Harrogate and District NHS Foundation Trust	Y	Apols	X	X	X	Joanna Cunnington	
Stuart Parkes	Chief Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	Y	Y	Y	Y	Apols (note Jane Crewe held voting rights)	
Dr Chris Hayes	Consultant and D&T Chair	York & Scarborough Teaching Hospitals NHS Foundation Trust	Y	X	X	Y (from 2.40pm)	Y (from 2.25pm)	Y	
Tracy Percival	Formulary Pharmacist	South Tees Hospitals NHS Foundation Trust	Y	Y	Y	Apols	Y	Y	
Richard Morris	Deputy Chief Pharmacist	Tees, Esk and Wear Valleys NHS Foundation Trust	Y	Y	Apols	Apols	Chris Williams	Y	
Angela Hall	Public Health representative	North Yorkshire County Council	Y	Kurt Ramsden	Apols	Kurt Ramsden	Kurt Ramsden	Apols	
Anita Dobson	Public Health representative	City of York Council	Y						
Alison Levin	Finance representative	North Yorkshire Place	Y	Jo Horsfall	Jo Horsfall	Jo Horsfall	Jo Horsfall	Apols	
Hazel Mitford	Lay/patient representative		Y	Y	Y	Y	Y	Y	
Gavin Mankin (Professional Secretary)	Principal Pharmacist Medicines Management	Regional Drug & Therapeutics Centre, Newcastle	N	Y	Y	Y	Dan Newsome	Y	
Chris Ranson	Lead Medicines Management Pharmacist: Commissioning and Formulary	North Yorkshire Place	N	Y	Y	Y	Y	Y	
Faisal Majothi	Medicines Optimisation Pharmacist	City of York Place	N	Y	Y	Apols	Y	Apols	
Jane Crewe	Formulary Pharmacist	York & Scarborough Teaching Hospitals NHS Foundation Trust	N	Y	Y	Y	Y	Y	

Sara Abbas-Llewelyn	Formulary Pharmacist	Harrogate and District NHS Foundation Trust	N	Sara Abbas-Llewelyn	Sara Abbas-Llewelyn	Sara Abbas-Llewelyn	Apols	Apols
Ian Dean	LPC Representative		N	Apols	Y	Apols	Y	Y
Dr Sally Tyrer	LMC Representative		N	Jane Raja	Jane Raja	Jane Raja	Jane Raja	Jane Raja
Sara Moore	Deputy Chief Pharmacist	Harrogate and District NHS Foundation Trust	N	Apols	See above	Apols	Y (2.15pm)	Y

The meeting was quorate with 10 out of 14 currently appointed voting members (or their deputies) in attendance and present throughout.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees, and papers should not be shared without agreement of the chair or professional secretary, to ensure confidentiality is maintained.

The meeting was chaired by Tim Rider.

Part 1

1. Apologies for absence and quoracy check

Shaun O’Connell, William Ovenden, Stuart Parkes, Faisal Majothi, Jo Horsfall, Kurt Ramsden

The APC noted that Laura Angus is now the ICB Chief Pharmacist for HNY and no longer aligned to York. Therefore, she will no longer have voting rights at NY&Y APC; these will be transferred to Chris Ranson who will hold voting rights for the medicines optimisation representative from York. The terms of reference will be update to reflect this.

The meeting was quorate.

2. Declarations of interest

Declarations of interest:

The Chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC’s Register of Interests. The Register is available via the professional secretary.

Declarations of interest from today’s meeting:

Nil declared.

3. Minutes of previous APC & decision summary of meeting held on 2nd August 2023

The minutes of the August 2023 APC were approved as a true and accurate record.

4. Outcome of items referred to August 2023 IPMOC

The August 2023 IPMOC was cancelled therefore TA902: Dapagliflozin for HFpEF has been referred to the September 2023 IPMOC meeting.

5. Matters arising not on the agenda & declarations of AOB

AOB: Semaglutide for weight loss now launched.

6. Action log

NICE TA 906: Rimegepant for preventing migraine

On today’s agenda.

Melatonin prescribing paper

NY MO team still to complete paper to submit to future APC outlining the current issues with

melatonin prescribing for consideration alongside the request to change the status.

TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction.

CH still to update HF guidance to support transfer of prescribing into primary care.

New Drug Applications - Tirbanibulin (Klisyri®▼, Almirall) 10mg/g ointment

On today's agenda.

Formulary Updates Approved at Aug 2023 APC

JC/SAL have updated Y&S and Harrogate formularies. ITEM NOW CLOSED.

Outstanding actions from previous APC meetings

Diazoxide for chronic intractable hypoglycaemia

KW/SM/JC to develop shared care guideline to be presented to next APC for approval.

Medical Devices Commissioning and Formulary Position

RDTc currently reviewing previous MCC commissioning positions on individual medical devices and will circulate an updated draft for comment before presenting at October 2023 APC for approval.

Oral minoxidil for androgenic alopecia

ICB policy alignment group have confirmed they will review this particular policy across the ICB when the NICE TA for baricitinib is published. Agreed no further action for item for APC until this policy is reviewed by the ICB.

NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management (update) - May 2023

KL has flagged to ICB need to review CGM policy in light of updated to NICE NG18 around use in children and young people with type 2 diabetes.

SP/KW to flag NICE NG18 updates re liraglutide, dulaglutide, or empagliflozin to arrive a consensus on updating the formulary. – *no update available.*

IQoro® medical device

RDTc to add to APC Medical Devices commissioning document to come to October 2023 APC.

Prostate letters – Bicalutamide face to face and remote

JC to go back to urology to ask if single letter can be adopted or that secondary care initiate both the bicalutamide and the LHRH analogue. To also confirm if a two-week delay in starting bicalutamide is clinically significant and removing the word "immediately" from the letter to manage patient interactions with GP practice.

Hydroxychloroquine and chloroquine retinopathy: Recommendations on monitoring 16 December 2020 – updated RCOphth guidelines

Work on adopting national shared care template is ongoing in NY&Y.

Part 2 – Governance

7. North Yorkshire & York APC Terms of Reference - Updated Sept 2023 – draft

An updated version was presented to and approved by the APC. Updated to reference latest policy on free of charge/compassionate use drugs from NHS England.

Part 3 – Mental Health

8. TEWV D&T Feedback – July 2023

Circulated for information.

9. Agomelatine formulary status

A request from TEWV to change agomelatine from RED to AMBER SI to harmonise across HNY and rest of TEWV patch was presented to and approved by the APC.

The APC approved the supporting information leaflet for primary care which is based on and existing version elsewhere in NENC subject to:

- Addition that no routine monitoring required in primary care and that LFT monitoring just required if clinically indicated.

ACTION:

- **JC/SAL to update the formulary websites.**

Part 4 – Formulary issues

10. Appeals against previous APC decisions

None received.

11. Formulary NICE TAs and MHRA Drug Safety Update – July 2023

The drugs in the following TAs to be reflected in the formulary as RED drugs in the relevant chapters with links to the TAs:

- TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
- TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer

The drugs in the following TAs to be reflected in the formulary as BLACK drugs in the relevant chapters with links to the TAs:

- TA909: Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

All the above TAs are NHSE-commissioned and would therefore have no cost impact to the ICB.

The drugs in the following TAs which are ICB-commissioned to be reflected in the formulary as AMBER SI drugs in the relevant chapters with links to the TAs:

- TA906: Rimegepant for preventing migraine

The ICB-commissioned drugs in the following TAs were received for information:

- TA910: Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)

Medicines Safety MHRA Drug Safety Update – July 2023

The group noted the drug safety updates for July 2023. The links are to be added to the relevant sections of the formulary.

ACTION:

- **JC/SAL to update the formulary websites.**
- **TA906: Rimegepant for preventing migraine exceeded the threshold for APC approval due to cost impact moving to primary care and will be presented to IPMOC for ratification.**

12. Other formulary issues

TA906 – Rimegepant for migraine

Approved as AMBER SI following confirmation of follow up arrangements in secondary care post August 2023 APC. Due to cost impact moving to primary care will be presented to IPMOC for ratification with an updated migraine pathway. Confirmed that the cost impact presented to APC was for the NY&Y footprint.

Blood glucose meter formulary

In April 2023, NHS England issued the commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets.

The Humber and North Yorkshire MMT in collaboration with specialists in HNY have reviewed the national recommendation and identified the preferred meters choices along with corresponding test strips and lancets for use in HNY.

The following local choices were approved by the APC:

Type 1

Patient Cohort	Meter Recommendations / price per 50 BG strips
Suitable for the majority of people that also require a ketone testing meter.	Preferred option: GlucoFix Tech GK - £5.95 (10 ketone strips £9.95) Other option: GlucoRx HCT - £8.95 (10 ketone strips £9.95)
Require additional functionality as per national recommendations	Preferred option: GlucoFix Tech GK - £5.95 (10 ketone strips £9.95) Other option: 4SURE Smart Duo - £8.99 (10 ketone strips £9.92)

Type 2

Suitable for the majority of people with Type 2 diabetes.	Preferred option: GlucoFix Tech GK - £5.95 Preferred option (elderly patients): Contour Plus Blue £5.95 Other option: Finetest Lite - £5.95
Require additional functionality as per national recommendations	Type 2 diabetes (enhanced functionality) AgaMatrix Agile (when launched) - £5.99 or AgaMatrix – WaveSense JAZZ wireless - £8.74 (until AgaMatrix Agile launched).
	Type 2 diabetes paediatrics Connect 2 Pharma – On Call Extra Mobile and On Call Extra Voice - £5.20
	Type 2 diabetes (Gestational diabetes - GDm-Health™) AgaMatrix – AgaMatrix Agile (when launched) - £5.99 or AgaMatrix – WaveSense JAZZ wireless- £8.74

Lancets

Lancets which are suitable for the majority of people with Type 1 and 2 diabetes, and those that require additional functionality.	Recommended lancets should be less than £3 per 100.
--	---

Noted also approved today at Humber APC and will go to September 2023 IPMOC for information.

13. New Drug Applications

Tirbanibulin (Klisyri®▼, Almirall) 10 mg/g ointment

Dr Ben Walker in attendance.

Requested for field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.

It has equal efficacy to 5-fluorouracil and imiquimod. Offers advantage of short duration of therapy (5 days) which will improve compliance. In applicant's practice approximately 10 to 20% of patients taking 5-fluorouracil do not complete the course due to the inflammatory reaction. This means that they go on to use a dermatology clinic slot. Imiquimod is also a long length of treatment and can occasionally cause systemic flu-like illness and can exacerbate some pre-

existing inflammatory diseases. Topical diclofenac is expensive, poor efficacy, very long duration of treatment (90 days).

The APC discussed and approved as RED drug to allow dermatology to gain experience of use and to be reviewed in six months. Efudix® remains first line whilst dermatology gain experience with tirbanibulin. Patients should not just be referred to dermatology for consideration of tirbanibulin. Felt longer term a GREEN RAG status would be appropriate but dermatology wish to gain real world experience of use first.

Diclofenac (Solaraze®) changed to RED in the treatment pathway for new patients who may require it.

ACTION:

- **JC/SAL to update the formulary websites.**

14. Compassionate use/free of charge scheme requests

Nil this month.

Part 5 – Shared Care and Guidelines (non-mental health)

15. Shared care guidelines for approval

Nil this month.

16. Humber and North Yorkshire Adult Asthma Guideline 2023

A new single Humber and North Yorkshire Children and Young People's Asthma Guideline was presented to and approved by the APC subject to ordering of inhalers being changed so that Fobumix not Symbicort is first.

Noted also approved today at Humber APC and will go to September 2023 IPMOC for information.

ACTION:

- **JC/SAL to update the formulary websites.**

17. Humber and North Yorkshire Children and Young People's Asthma Guideline 2023

A new single Humber and North Yorkshire Children and Young People's Asthma Guideline was presented to and approved by the APC.

Noted also approved today at Humber APC and will go to September 2023 IPMOC for information.

ACTION:

- **JC/SAL to update the formulary websites.**

Part 6 – Other items of business

18. NHS England items which should not routinely be prescribed in primary care policy guidance – Aug 2023

This updated national guidance was presented to the APC for information. Changes as per accompanying FAQs document. Suggest APC DNP list and formulary be updated to reflect this new document as appropriate. Note tadalafil once daily now removed from guidance.

Previous West Yorkshire & Harrogate liothyronine policy may also require a review.

The APC noted the ongoing work in NY&Y by the Medicines Optimisation Team on this.

Part 7 – Standing items (for information only)

19. IPMOC minutes – July 2023

Not yet available.

20. **TEVV D&T minutes – March 2023**
Not yet available.
21. **York & Scarborough Trust Drug and Therapeutics Committee minutes – since May 2023**
Not yet available.
22. **Harrogate Trust Medicines and Therapeutics Group minutes – since September 2022**
Not yet available.
23. **West Yorkshire ICS APC Minutes – since March 2023**
Not yet available.
24. **Humber APC minutes – July 2023**
Circulated for information.
25. **Humber APC decisions & recommendations – July and August 2023**
Circulated for information.
26. **RDTC Monthly Horizon scanning – August 2023**
Circulated for information.
27. **NENC Medicines Committee decision Summary – August 2023**
Not yet available.

Any Other Business

Semaglutide for obesity

The APC noted that following the publication of NICE TA875 in March 2023 the product was launched on limited basis in the UK as of the 4th September 2023. In May 2023 the APC deferred a decision on formulary status until the product was launched in the UK and its price was known. Agreed to bring back to October 2023 APC with accurate local cost impact so that a decision of formulary RAG status can be taken.

ACTION:

- **CR to bring paper including cost impact of semaglutide for obesity (NICE TA875) to October 2023 APC.**
- **JC to check YSFT service capacity.**
- **TP to check STHFT service capacity for North Yorkshire patients.**

The disclosure of industry payments to the healthcare sector – national consultation

The current national consultation on the disclosure of industry payments to the healthcare sector which closes on 16th October 2023 was promoted to APC members if they wish to respond individually.

Formulary applications received for October 2023 meeting

The APC have received the following formulary applications to date for the October 2023 APC meeting:

- Nil to date.

Date and time of next meeting

Wednesday 4th October 2023, 2pm – 4.30pm, virtual meeting via Microsoft Teams